| Literature DB >> 35656594 |
Christian Simon1, Avinash Beharry1, Vinidh Paleri2, Pascaline Dübi1, Karma Lambercy1, F Christopher Holsinger3, Jelena Todic1.
Abstract
We report on the first clinical experience with the robotic-assisted extended "Sistrunk" approach (RESA) for access to constrained spaces of the upper aerodigestive tract. This prospective case cohort study include six patients that underwent RESA if transoral exposure could not be achieved. Three patients received previous radiation. Patients were postoperatively followed until week 16 for perioperative complications, surgical margins, and functional outcomes. In all patients RESA allowed adequate exposure and resection with negative margins. Three patients who underwent salvage surgery experienced a minor or intermediate grade postoperative bleeding. No patient developed a pharyngocutaneous fistula. Three patients recovered their swallowing to their preoperative status and the remaining three experienced an improvement. All patients experienced complete recovery of their voice. RESA has the potential to provide a new organ preservation approach for head and neck cancer (HNC) not amenable to transoral exposure and thus warrants further prospective clinical studies.Entities:
Keywords: Sistrunk procedure; da Vinci; endoscopic surgery; head and neck surgery; robotic surgery
Mesh:
Year: 2022 PMID: 35656594 PMCID: PMC9546007 DOI: 10.1002/hed.27114
Source DB: PubMed Journal: Head Neck ISSN: 1043-3074 Impact factor: 3.821
Patient characteristics with previous oncological history
| Patient | Age | Localization | Clinical staging | Pathological staging | Closest margin (cm) | Hospital stay (days) | Complications related to surgery (surgical and medical) | Oncological history (site, staging, treatment) |
|---|---|---|---|---|---|---|---|---|
| 1 Supraglottis | 63 | Supraglottis | cT1 cN0 cM0 | pT2 cN0 cM0 | 0.5 | 29 |
Bleeding, D18 Pneumonia, D20 | Left oropharyngeal SCC, pT2 ypN3b cM0 p16 negative Left lateral pharyngectomy and left ND (ECE+), adjuvant RT with 66 Gy for the tumoral site, 59.4 Gy for the intermediate area, and 52.8 Gy for the ND area, 07/2016 Regional recurrence, right radical ND, adjuvant CRT with Cisplatin, 66 Gy by tomotherapy and 52.8 Gy for the ND area, 06/2019 |
| 2 Supraglottis | 54 | Supraglottis | cT3 cN1 cM0 | pT3 cN1 cM0 | 0.5 | 26 | None | Adenocarcinoma, right superior lobe, cT3 cN2 cM1 Stereotaxic RT with 20 and 33 Gy for cerebral metastasis, 06/2019, and 55 Gy for pulmonary metastasis, 03/2020 Pembrolizumab since 07/2019 |
| 3 Postcricoid | 90 | Postcricoid | cT1 cN1 cM0 | pT1 pN1 M0 | 0.2 | 42 | Bleeding, D12 |
Right periauricular cutaneous SCC, pT2 pN3b (ECE+) Tumor resection, superficial parotidectomy, radical ND with extracapsular extension, RT with 51.2 Gy for the tumoral site, 51.2 Gy for the lymph node, and 44.8 Gy for the ND area, 08/2020 Without chemotherapy because of age Multiple cutaneous SCC and BCC: right pinna, nose root, right tempel, thorax Tumor resection, 10/2017–01/2020 |
| 4 Postcricoid | 55 | Postcricoid | cT1 cN3b cM0 | pT1 cN3b cM0 | 0.2 | 16 | Pneumonia, D9 | No oncological history |
| 5 Base‐of‐tongue | 68 | Base of tongue | cT3 cN0 cM0 | pT3 cN0 cM0 | 0.4 | 30 | Bleeding, D12 | Multiple synchronous SCCs: oral cavity cT2 (soft palate) and pTis (floor of the mouth), oropharynx cT4a, and pulmonary cT1, cN2c cM0: Tumor resection of oral cavity cancers, Cetuximab and RT with 69.96 Gy for the oropharynx primary, and 66 Gy for the pulmonary lesion, 7/2020 |
| 6 Piriform sinus | 52 | Piriform Sinus | cT2 N3b cM0 | pT2 pN3b cM0 | 0.1 | 23 | No oncological history |
Abbreviations: BCC, basal cell carcinoma; CRT, radiochemotherapy; CT, chemotherapy; D, day postoperative; ECE+, lymph node with extracapsular extension; Gy, Gray; ND, neck dissection; RT, radiotherapy; SCC, squamous cell carcinoma.
Corresponds to deep margin at M. constrictor inferior (R0).
Swallowing outcome and aspiration/penetration
| Patient and subsite | Preop. FOIS | Preop. voice | Postop. voice | Tube feeding (days) | Tracheotomy (days) | Ambulatory speech therapy sessions | FOISW1 | FOIS W4 | FOIS W8 | FOIS W12 | FOIS W16 | PAS W1 | PAS W4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 Supraglottis | 4 | G1 R1 B0 A0 S1 | G1 R1 B0 A0 S1 | 95 | 16 | 6 | 2 | 3 | 3 | 3 | 4 | 6 | 2 |
| 2 Supraglottis | 6 | G0 | G0 | 26 | 20 | 9 | 2 | 7 | 7 | RT | RT | 4 | 1 |
| 3 Postcricoid | 5 | G1R1B0 A1 S0 | G1R1B0 A1 S0 | 55 | 32 | 2 | 2 | 3 | 5 | 6 | 6 | 4 | 2 |
| 4 Postcricoid | 5 | G1 R1 B0 A0 S0 | G1 R1 B0 A0 S0 | 15 | 11 | 2 | 3 | 5 | RT | RT | RT | 4 | 1 |
| 5 Base‐of‐tongue | 5 | G1 R1 B0 A0 S0 | G1 R1 B0 A0 S0 | 43 | 88 | 4 | 1 | 2 | 2 | 3 | 5 | 3 | 1 |
| 6 Piriform sinus | 6 | G0 | G0 | 50 | 15 | 0 | 5 | 7 | 7 | RT | RT | 3 | 1 |
Note: Gray color indicates previous RT.
Abbreviations: FOIS, Functional Oral Intake Scale; GRBAS, Grade; Roughness; Breathiness; Asthenia; Strain; PAS, Penetration and Aspiration Scale; RT, radiation therapy; W, weeks after surgery.